
WHAT IS CLAIMED IS:

1. Use of a combination of compounds in the manufacture of a medicament for treating a disease or condition, wherein the combination includes an effective amount of Compound (A), or a pharmaceutically acceptable salt thereof, and an effective amount of Compound (B), or a pharmaceutically acceptable salt thereof, wherein:


the Compound (A) has the structure:




(A); and

the Compound (B) is a WEE1 inhibitor, or a pharmaceutically acceptable salt thereof,


wherein the WEE1 inhibitor is selected from the group consisting of



(AZD1775), NUV-569, IMP7068, Debio 0123,



(SC0191) and



(PD0166285), or a pharmaceutically acceptable salt of any of the foregoing;

wherein Compound (A), or a pharmaceutically acceptable salt thereof, and Compound (B), or a pharmaceutically acceptable salt thereof, are provided in a single pharmaceutical composition or separate pharmaceutical compositions.

2. The use of Claim 1, wherein Compound (A), or a pharmaceutically acceptable salt thereof, is provided prior to Compound (B), or a pharmaceutically acceptable salt thereof.

3. The use of Claim 1, wherein Compound (A), or a pharmaceutically acceptable salt thereof, is provided concomitantly with Compound (B), or a pharmaceutically acceptable salt thereof.

4. The use of Claim 1, wherein Compound (A), or a pharmaceutically acceptable salt thereof, is provided subsequent to Compound (B), or a pharmaceutically acceptable salt thereof.

5. The use of any one of Claims 1-4, wherein the disease or condition is selected from the group consisting of a breast cancer, a cervical cancer, an ovarian cancer, an uterine cancer, a vaginal cancer, a vulvar cancer, a brain cancer, a cervicocerebral cancer, an esophageal cancer, a thyroid cancer, a small cell cancer, a non-small cell cancer, a lung cancer , a stomach cancer, a gallbladder/bile duct cancer, a liver cancer, a pancreatic cancer, a colon cancer, a rectal cancer, a choriocarcinoma, an uterus body cancer, an uterocervical cancer, a renal pelvis/ureter cancer, a bladder cancer, a prostate cancer, a penis cancer, a testicular cancer, a fetal cancer, a Wilms' cancer, a skin cancer, a malignant melanoma, a neuroblastoma, an osteosarcoma, an Ewing's tumor, a soft part sarcoma, an acute leukemia, a chronic lymphatic leukemia, a chronic myelocytic leukemia, polycythemia vera, a malignant lymphoma, multiple myeloma, a Hodgkin's lymphoma, and a non-Hodgkin’s lymphoma.

6. The use of Claim 5, wherein the disease or condition is a breast cancer.

7. The use of any one of Claims 5-6, wherein the breast cancer that does not include any point mutations ER mutations.

8. The use of any one of Claims 5-6, wherein the breast cancer is ER positive breast cancer.

9. The use of any one of Claims 5-8, wherein the breast cancer is ER positive/HER2-negative breast cancer.

10. The use of any one of Claims 5-9, wherein the breast cancer has been previously treated with an endocrine therapy.

11. The use of Claim 10, wherein the treatment was with a selective ER modulator (SERM).

12. The use of Claim 10, wherein the treatment was with a selective ER degrader (SERD).

13. The use of Claim 10, wherein the treatment was with an aromatase inhibitor.

14. The use of Claim 13, wherein the aromatase inhibitor is a steroidal aromatase inhibitor.

15. The use of Claim 13, wherein the aromatase inhibitor is a non-steroidal aromatase inhibitor.

16. The use of any one of Claims 5-9, wherein the breast cancer has not been previously treated.

17. The use of any one of Claims 5-16, wherein the breast cancer is present in a postmenopausal woman.

18. The use of any one of Claim 5-17, wherein the breast cancer is present in a subject that has a serum estradiol level in the range of >15 pg/mL to 350 pg/mL.

19. The use of any one of Claim 5-17, wherein the breast cancer is present in a subject that has a serum estradiol level ≤ 15 pg/mL.

20. The use of any one of Claim 5-17, wherein the breast cancer is present in a subject that has a serum estradiol level ≤ 10 pg/mL.